Sector News

Genmab transfers its ofatumumab collaboration from GSK to Novartis

November 3, 2014
Life sciences
Danish biotech company Genmab has entered into an agreement with UK pharma major GlaxoSmithKline and Swiss drug major Novartis to transfer the ofatumumab collaboration, currently with GSK, to Novartis.
 
This follows an announcement in April 2014 that Novartis would acquire GSK’s oncology products, and the transfer of ofatumumab will only become effective on the closing of the GSK/Novartis transaction, expected in the first half of next year.
 
Upon transfer, Novartis is to develop and commercialize ofatumumab in oncology indications and GSK would continue to develop and commercialize the drug for autoimmune indications. The terms of the deal state that Genmab is not required to pay existing funding liabilities, or to fund research and development costs beyond December 31, 2014.
 
Jan van de Winkel, chief executive of Genmab, said: “The collaborations with Novartis and GSK for this innovative therapeutic antibody will help ofatumumab reach its fullest potential, while improving cash flows.”
 
Additionally, on completion of the transfer of the collaboration, Genmab will be able to develop follow-on CD20 products.
 

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach